Table 1.
Table summarizing the distribution of p.L858R and DelEx19 positive and negative patients found with NGS‐56G assay
| Resistance Mt | Princeps Mt | |||
|---|---|---|---|---|
| OncoBEAM™‐EGFR p.T790M | NGS‐56G | |||
| p.L858R or DelEx19 positive | p.L858R or DelEx19 negative | p.L858R or DelEx19 positive | L858R or DelEx19 negative | |
| p.T790M positive (N; %) | 33 (43.8%) | 7 (6.6%) | 20 (25.9%) | 0 |
| Mean allelic frequency in % (SD) | 1.4261 (3.1315) | 0.1146 (0.1102) | 6.2 (12.7) | — |
| p.T790M negative (N; %) | 44 (57.2%) | 99 (92.4%) | 57 (73.7%) | 106 (100%) |
| Mean allelic frequency in % (SD) | 0.0084 (0.0074) | — | 0.01 (6 × 10−19) | — |
| Total (N) | 77 | 106 | 77 | 106 |
EGFR, epidermal growth factor receptor; NGS, next‐generation sequencing.
For these two categories, the number of patients harboring the resistance mutation p.T790M is annotated for OncoBEAM™‐EGFR assay and NGS‐56G assay, respectively.